FDA accepts new drug application for Sumitomo Pharmaceuticals dasotraline to treat BED
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, SumitomoPharmaceutical(http://u.Ssub-
company(http://Sunovion Pharma announced that the U.SFood andMedicines(http://Administration (
FDA(http://) has accepted the treatment of dasotra (dassoquer) for the treatment of moderate to severe eating disorder (BED)new drug(http:// About dasotraline
dasotraline is a new type of dual-effect dopamine and norepinephrine reuptake inhibitor (DNRI) that inhibits pre-synaptic retake of dopamine and norepinephrine in the central nervous system (CNS) and does not stimulate the release of dopamine and norepinephrine neurons Dasotraline is developing treatments for adults with moderate to severe BED The pharmacokinetic characteristics of dasotraline are the ability to extend half-life and support its potential for continuous control of moderate to severe BED symptoms Sunovion is also evaluating the drug for use in other potential indications, including attention deficit hyperactivity disorder (ADHD) Dasotraline is a daily drug that has been shown to treat moderate to severe BED in two 12-week randomized, placebo-controlled, critical Phase III studies (SEP360-221, SEP360-321) In clinical studies, including long-term safety studies sEP360-322, which included the evaluation of severe BED in treatment, dasotraline was found to have good tolerance
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
